English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, May 22, 2023
中國抗體SM17針對治療哮喘的新藥研究申請獲國家藥監局藥品審評中心受理
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE
Monday, December 19, 2022
中国抗体荣获“第七届金港股”评选中“最具价值医药及医疗公司”奖项
中國抗體榮獲「第七屆金港股」評選中「最具價值醫藥及醫療公司」獎項
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"
Friday, November 4, 2022
中国抗体宣布委任王善春先生为中国区总裁
中國抗體宣佈委任王善春先生為中國區總裁
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company
Tuesday, October 18, 2022
访中国抗体制药创办人梁瑞安:现是香港发展创科最好时候
訪中國抗體製藥創辦人梁瑞安:現是香港發展創科最好時候

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575